How do the results of the RADIANT trials impact on the management of NET patients? A systematic review of published studies

Sara Pusceddu _, Filippo De Braud, Giuseppe Lo Russo, Laura Concas, Daniela Femia, Claudio Vernieri, Alice Indini, Barbara Formisano and Roberto Buzzoni

PDF  |  HTML  |  How to cite

Oncotarget. 2016; 7:44841-44847. https://doi.org/10.18632/oncotarget.8601

Metrics: PDF 2465 views  |   HTML 2060 views  |   ?  


Sara Pusceddu1,2, Filippo De Braud1,2, Giuseppe Lo Russo1,2, Laura Concas1,2, Daniela Femia1,2, Claudio Vernieri1,2, Alice Indini1,2, Barbara Formisano1,2 and Roberto Buzzoni1,2

1 Medical Oncology Department, ENETs Center of Excellence, Milan, Italy

2 Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

Correspondence to:

Sara Pusceddu, email:

Keywords: everolimus, neuroendocrine tumors

Received: December 14, 2015 Accepted: March 10, 2016 Published: April 05, 2016


In the last five years, everolimus has demonstrated efficacy in the treatment of neuroendocrine tumors (NETs) of different origins; its efficacy and safety were explored in the RADIANT trials, the last of which (RADIANT-4) has been recently published (December 2015). Overall, evidence collected from the RADIANT studies holds promise to change clinical practice for the treatment of NETs.

In this paper, we comment on the role of everolimus within the therapeutic algorithm for NETs treatment, based on the systematic analysis of the RADIANT trials and our experience.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 8601